ESTRO 2024 - Abstract Book

S683

Clinical - Breast

ESTRO 2024

50, 60 and 70yr old respectively. The threshold dose level for a 5% RIAR-ACE-10 for the same comorbidities was 5.8, 3.81, 2.25 and 1.31 Gy for a 40, 50, 60 and 70yr-old patient, respectively

The calculated RIAR-ACE-Life at an MHD 4 Gy was > 5% for obese-diabetic and obese-diabetic-hypertensive patients of all ages; theRIAR-ACE-10 was > 5% over baseline risk in obese-diabetic and obese-diabetic-hypertensive women aged ≥50yrs.

Clinical assessment and competing risks of mortality due to the cancer would impact the choice of lifetime versus 10yr risk estimation.

Caveats include the hypothetical nature of this estimation, the performance of the QRisk and Darby models, and the lack of quantification of the impact of cardiotoxic chemotherapy and cardiac substructure dose.